Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION
**DOSAGE AND ADMINISTRATION** When used as monotherapy, the dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily. When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of TRUSOPT in the affected eye(s) two times daily. When substituting TRUSOPT for another ophthalmic antiglaucoma agent, discontinue the other agent after proper dosing on one day, and start TRUSOPT on the next day. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
OPHTHALMIC
Medical Information
**INDICATIONS** TRUSOPT Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with: - ocular hypertension - open-angle glaucoma - pseudoexfoliative glaucoma and other secondary open-angle glaucomas
**CONTRAINDICATIONS** TRUSOPT is contraindicated in patients who are hypersensitive to any component of this product.
S01EC03
dorzolamide
Manufacturer Information
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Santen Pharmaceutical Co., Ltd. Noto Plant
Active Ingredients
Documents
Package Inserts
Trusopt Opthalmic Solution 2% PI.pdf
Approved: October 25, 2021